278 related articles for article (PubMed ID: 27058426)
1. Molecules that target nucleophosmin for cancer treatment: an update.
Di Matteo A; Franceschini M; Chiarella S; Rocchio S; Travaglini-Allocatelli C; Federici L
Oncotarget; 2016 Jul; 7(28):44821-44840. PubMed ID: 27058426
[TBL] [Abstract][Full Text] [Related]
2. Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization.
Federici L; Falini B
Protein Sci; 2013 May; 22(5):545-56. PubMed ID: 23436734
[TBL] [Abstract][Full Text] [Related]
3. Nucleophosmin in Its Interaction with Ligands.
Cela I; Di Matteo A; Federici L
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664415
[TBL] [Abstract][Full Text] [Related]
4. Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 Mediate the cellular localization of nucleophosmin and its AML-associated mutants.
Mukherjee H; Chan KP; Andresen V; Hanley ML; Gjertsen BT; Myers AG
ACS Chem Biol; 2015 Mar; 10(3):855-63. PubMed ID: 25531824
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel nucleophosmin-interaction motif in the tumor suppressor p14arf.
Luchinat E; Chiarella S; Franceschini M; Di Matteo A; Brunori M; Banci L; Federici L
FEBS J; 2018 Mar; 285(5):832-847. PubMed ID: 29283500
[TBL] [Abstract][Full Text] [Related]
6. Nucleophosmin: a versatile molecule associated with hematological malignancies.
Naoe T; Suzuki T; Kiyoi H; Urano T
Cancer Sci; 2006 Oct; 97(10):963-9. PubMed ID: 16984370
[TBL] [Abstract][Full Text] [Related]
7. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF.
Bolli N; De Marco MF; Martelli MP; Bigerna B; Pucciarini A; Rossi R; Mannucci R; Manes N; Pettirossi V; Pileri SA; Nicoletti I; Falini B
Leukemia; 2009 Mar; 23(3):501-9. PubMed ID: 19005479
[TBL] [Abstract][Full Text] [Related]
8. Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases.
Colombo E; Alcalay M; Pelicci PG
Oncogene; 2011 Jun; 30(23):2595-609. PubMed ID: 21278791
[TBL] [Abstract][Full Text] [Related]
9. Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers.
Jeong EG; Lee SH; Yoo NJ; Lee SH
APMIS; 2007 Apr; 115(4):341-6. PubMed ID: 17504301
[TBL] [Abstract][Full Text] [Related]
10. Implication of B23/NPM1 in Viral Infections, Potential Uses of B23/NPM1 Inhibitors as Antiviral Therapy.
Lobaina Y; Perera Y
Infect Disord Drug Targets; 2019; 19(1):2-16. PubMed ID: 29589547
[TBL] [Abstract][Full Text] [Related]
11. [Nucleophosmin mutations in hematological malignancies - review].
Luo ZP; Zhang L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):662-6. PubMed ID: 17605889
[TBL] [Abstract][Full Text] [Related]
12. Nucleophosmin mutations alter its nucleolar localization by impairing G-quadruplex binding at ribosomal DNA.
Chiarella S; De Cola A; Scaglione GL; Carletti E; Graziano V; Barcaroli D; Lo Sterzo C; Di Matteo A; Di Ilio C; Falini B; Arcovito A; De Laurenzi V; Federici L
Nucleic Acids Res; 2013 Mar; 41(5):3228-39. PubMed ID: 23328624
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?
Falini B; Gionfriddo I; Cecchetti F; Ballanti S; Pettirossi V; Martelli MP
Blood Rev; 2011 Nov; 25(6):247-54. PubMed ID: 21724308
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.
Falini B
Cancer Treat Res; 2010; 145():149-68. PubMed ID: 20306250
[TBL] [Abstract][Full Text] [Related]
15. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
[TBL] [Abstract][Full Text] [Related]
16. Proteomics analysis identifies the ribosome associated coiled-coil domain-containing protein-124 as a novel interaction partner of nucleophosmin-1.
Çakırca G; Öztürk MT; Telkoparan-Akillilar P; Güllülü Ö; Çetinkaya A; Tazebay UH
Biol Cell; 2024 Jan; 116(1):e202300049. PubMed ID: 38029384
[TBL] [Abstract][Full Text] [Related]
17. Structure of nucleophosmin DNA-binding domain and analysis of its complex with a G-quadruplex sequence from the c-MYC promoter.
Gallo A; Lo Sterzo C; Mori M; Di Matteo A; Bertini I; Banci L; Brunori M; Federici L
J Biol Chem; 2012 Aug; 287(32):26539-48. PubMed ID: 22707729
[TBL] [Abstract][Full Text] [Related]
18. Nucleophosmin C-terminal leukemia-associated domain interacts with G-rich quadruplex forming DNA.
Federici L; Arcovito A; Scaglione GL; Scaloni F; Lo Sterzo C; Di Matteo A; Falini B; Giardina B; Brunori M
J Biol Chem; 2010 Nov; 285(48):37138-49. PubMed ID: 20858903
[TBL] [Abstract][Full Text] [Related]
19. Erythroid differentiation-associated gene interacts with NPM1 (nucleophosmin/B23) and increases its protein stability, resisting cell apoptosis.
Zhang MJ; Ding YL; Xu CW; Yang Y; Lian WX; Zhan YQ; Li W; Xu WX; Yu M; Ge CH; Ning HM; Li CY; Yang XM
FEBS J; 2012 Aug; 279(16):2848-62. PubMed ID: 22712502
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for the recognition by 14-3-3 proteins of a conditional binding site within the oligomerization domain of human nucleophosmin.
Kapitonova AA; Tugaeva KV; Varfolomeeva LA; Boyko KM; Cooley RB; Sluchanko NN
Biochem Biophys Res Commun; 2022 Oct; 627():176-183. PubMed ID: 36041327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
